| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We explored a candidate for a novel transthyretin (TTR) amyloloidogenesis inhibitor that binds to the TTR monomer. We found diacerein, a anti-inflammatory drug, as a candidate of a TTR amyloidogenesis inhibitor by computer-aided screening and screening of in-house compound library. We discovered by biophysical experiments that while diacerein stabilized the TTR tetramer by binding to TTR in a same manner as other TTR amyloidogenesis inhibitors, diacerein inhibited the TTR amyloid fibril formation of TTR by stabilizing the TTR monomer and dimer. Altough further investigation is required, our study indicates diacerein would be a novel TTR amyloidogenesis inhibitor.
|
